Recent Research Analysts’ Ratings Changes for Takeda Pharmaceutical (TAK)

A number of research firms have changed their ratings and price targets for Takeda Pharmaceutical (NYSE: TAK):

• 7/6/2026 – Takeda Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/29/2026 – Takeda Pharmaceutical was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/28/2026 – Takeda Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/23/2026 – Takeda Pharmaceutical was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 6/20/2026 – Takeda Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/16/2026 – Takeda Pharmaceutical was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.